F2RL1 and colorectal cancer: In this study, we extend our prior observation that atorvastatin and rosuvastatin selectively suppress protease-activated receptor 2 expression in LPS primed colorectal cancer cells while leaving protease-activated receptor 1 unchanged, and we map the downstream signalling and fate consequences of that receptor level modulation.